Clinical Research Directory

Inclusion Criteria: * Pathologically confirmed invasive cervical cancer * FIGO IB1-IIA * Squamous cell cancer or HPV-related adenocarcinoma * Presence of tumour-related risk factors as follows: 1. tumour ≥4 cm OR 2. tumour\>2 cm \<4 cm AND lymphovascular space invasion OR 3. tumour \>2 cm \<4 cm AND tumour free distance \<3 mm OR 4. tumour \>2 cm \<4 cm AND deep stromal invasion (\>2/3) * No evidence of suspicious pelvic lymph nodes or distant metastases on imaging (by radiological subjective assessment before surgery and negative pelvic LN on final pathology) * ECOG performance status 0-1 * Deemed suitable and fit for radical surgery followed by adjuvant radiotherapy * Negative pregnancy test (if applicable) * Negative HIV test (only performed in high-risk countries or patients who have moved from those countries within the past 10 years) Exclusion Criteria: * Adenosquamous cancer or adenocarcinoma unusual type (non-HPV related - such as: mucinous, clear cell, mesonephric) or other rare tumour types (those not listed in the inclusion criteria) * Inconclusive primary site of disease * Unequivocally positive lymph node by imaging (by radiological subjective assessment) * FIGO \<IB1 / \>IIA * Previous pelvic malignancy * History of second primary cancer outside pelvis if ≤ 3 years complete clinical remission (CCR) * Previous pelvic radiotherapy * Neoadjuvant chemotherapy prior surgical treatment * Low likelihood of patient compliance to the follow-up